| 产品描述: | Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (Mpro and 3CLpro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19. |
| 体外研究: |
Ibuzatrelvir (0-500 mg/kg,口服,单次剂量) 在小鼠适应的 SARS-CoV-2 动物模型中以剂量依赖的方式抑制病毒复制[4]。 Ibuzatrelvir在大鼠和猴子体内的药动学[1] |
| 体内研究: |
Ibuzatrelvir (0-10000 nM,3 天) 抑制 SARS-CoV-1 Mpro 和 MERS Mpro 活性的 IC50 值分别为 18 nM 和 930 nM。Ibuzatrelvir 在 VeroE6、MRC-5 或 Vero81 细胞中,显示出 SARS-CoV-2 Mpro 以及相关人冠状病毒蛋白水解活性的有效抑制剂。 Ibuzatrelvir 在分化的正常人支气管上皮 (dNHBE) 细胞中表现出较强的抗病毒活性,EC50 和 EC90 值分别为 34 nM 和 70 nM。 |
| 参考文献: |
1. Owen, et al. Preparation of peptidomimetic nitriles as SARS-CoV-2 3CL protease inhibitors and methods for the treatment of COVID-19. World Intellectual Property Organization, WO2021250648 A1. 2021-12-16. 2. Mahta Mortezavi, et al. Virologic Response and Safety After Oral Administration of Ibuzatrelvir, a Novel SARS-CoV-2 Mpro Inhibitor, in Non-Hospitalized Adults With Symptomatic COVID-19. European Congress of Clinical Microbiology and Infectious Disease (ECCMID) 2024; 2024 April 27-30. 3. Westberg M, et al. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations[J]. Sci Transl Med. 2024 Mar 13;16(738):eadi0979. 4. Allerton CMN, et al. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19[J]. J Med Chem. 2024 Apr 30. |
| 保存条件: |
-80°C 12个月; -20°C 6个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.043 ml |
10.215 ml |
20.429 ml |
| 5 mM |
0.409 ml |
2.043 ml |
4.086 ml |
| 10 mM |
0.204 ml |
1.021 ml |
2.043 ml |
| 50 mM |
0.041 ml |
0.204 ml |
0.409 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |